Viridian Therapeutics Q3 2026 Earnings Call - VIRIDIAN THERAPEUTICS INC

Explicit Guidance:

• No specific quantitative financial guidance (revenue, earnings, margins, or cash flow) provided for future quarters or fiscal years; management explicitly declined to give Q4 or FY2027 numerical guidance, stating revenue growth rates will be determined after observing subsequent quarters.
• J-Code Timeline: Permanent J-code for LUMBOA assigned by CMS, effective January 1, 2027.
• Payer Coverage Targets: On track to achieve "broad coverage" (critical mass) within 6 to 9 months from launch; currently at 30% covered lives with policies in place as of Q3 2026 exit.

Business-Segment Outlook:

• LUMBOA (TED): Exceeded expectations in Q1 launch ($24.7M revenue, >100 patients on therapy); strategy focuses on conversion of the 2,000 core prescribers (80% of IGF-1R market). Anticipated to drive significant long-term growth beyond the current ~$2B market run rate.
• ELLI (Subcutaneous Anti-IGF-1R): Next-generation product designed for self-administration every 8 weeks; potential to improve patient experience and expand treatment to home settings.
• VRDN008 (FcRN Inhibitor): First-in-human results expected later this quarter; designed for half-life extension and less frequent dosing.
• VRDN292 (Anti-TSHR): Potential best-in-class candidate for Graves' disease; Phase 1 trial initiation expected later this quarter with subcutaneous delivery.

Market and Competitive Outlook:

• Market Dynamics: Anticipates no "bolus" demand; patient influx is expected to be gradual due to the urgent, progressive nature of Thyroid Eye Disease (TED).
• Share Gain: Strategy is conversion of existing IGF-1R users; early signals show both experimentation and wholesale switching by core prescribers.
• Payer Parity: Aims for insurance coverage parity with competitor Tepezza in almost all cases to facilitate physician choice; acknowledges interim medical exception processes will be utilized for non-covered plans.
• Market Expansion: Open to the possibility of market expansion (beyond current $2B run rate) driven by LUMBOA's rapid and durable clinical profile, though initial focus remains on conversion.

Macro / Industry Outlook:

• Regulatory: Successful navigation of CMS J-code application within tight windows post-approval.
• Operational: Expect continued reliance on established referral pathways and core prescriber relationships; no specific macroeconomic, interest rate, or FX risks highlighted as material drivers.

Strategic Initiatives:

• Pipeline Advancement: Commitment to leveraging existing commercial infrastructure and execution team to accelerate next-generation assets (ELLi, VRDN292, FcRN portfolio) without delay.
• Market Access: Continued engagement with payers to establish policies; deployment of "Viridian Cares" patient support team to facilitate treatment initiation and adherence.
• Cash Management: Maintaining strong liquidity ($955M cash, equivalents, and marketable securities) to fund current business plans through profitability.
• External Growth: Continuation of internal discovery and evaluation of external M&A or partnership opportunities.

Risks and Headwinds to Outlook:

• Payer Adoption Timing: Policy adoption by payers may lag approval; 70% of covered lives do not yet have formal policies in place (though interim access mechanisms exist).
• Execution Variance: Management emphasizes the need to see sustained trends over subsequent quarters before confirming long-term growth rates or "exit velocity."
• Data Uncertainty: Future clinical data for VRDN008 and ELLI remains to be confirmed; no guarantees on timing or specific threshold achievement for IGF reduction or albumin sparing.
• Market Size Assumptions: While current market is ~$2B, actual expansion potential remains unproven and subject to physician adoption rates.

Management Tone on the Future:

• High Confidence: Expressed "extreme pride" in Q1 execution, describing the team as "firing on all cylinders" and "executing at an extremely high level."
• Repeatable Success: CEO and CCO view the current LUMBOA launch as a repeatable playbook for future assets (ELLi, etc.), citing strong product profile, right people, and clear strategy.
• Cautious Optimism: While "encouraged" and "excited" by early demand, management consistently hedges against early volatility, stating they "need to see this play out over subsequent quarters" to validate sustained uptake.

Miscellaneous:

• Revenue Recognition: Recognized upon receipt by specialty distributors; flexible payment terms provided to infusion centers during the interim J-code period to manage cash flow.
• Patient Demographics: Target audience primarily women aged 40–50; historical therapy mix is ~80% active disease, 20% chronic, a mix the company anticipates maintaining initially.